Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25954048 | 0.83 | HTR1A (0.41) | DRD2HTR1A | |
| SCHEMBL29118108 | 0.82 | HTR2C (0.47) | MAOATSHRHTR2CDRD2MEN1 | |
| SCHEMBL29885479 | 0.79 | MAOA (0.54) | MAOATSHRHTR2CCYP2D6HSD17B10 | |
| Hydrochloric Acid SCHEMBL2792263 | 0.78 | MEN1 (0.59) | HTR2CMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2796822 | 0.78 | PRCP (0.54) | MAOAHTR2CDRD2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2796024 | 0.78 | PRCP (0.54) | MAOAHTR2CDRD2MEN1KMT2A | |
| SCHEMBL7818489 | 0.77 | HTR2C (0.42) | MAOATSHRHTR2CHSD17B10DRD2 | |
| SCHEMBL19684822 | 0.77 | HTR2C (0.42) | MAOATSHRHTR2CHSD17B10DRD2 | |
| SCHEMBL19684816 | 0.77 | HTR2C (0.42) | MAOATSHRHTR2CHSD17B10DRD2 | |
| SCHEMBL2795781 | 0.77 | HTR1A (0.50) | HTR2CDRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263607-B2 | 1-substituted tetrahydroisoquinoline compound | ASTELLAS PHARMA INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | CACNA1S, CACNA1E, CACNA1B | MAOA 606/4885TSHR 3390/4885HTR2C 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.